Compare Live Nation Entertainment, Inc. (LYV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs TG Therapeutics Inc — how do they compare? Live Nation Entertainment, Inc. trades at $170.33 (market cap $39.92B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Live Nation Entertainment, Inc. is far larger — about 4.9× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Live Nation Entertainment, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and TG Therapeutics Inc for 16 Days on average.
| LYV | TGTX | |
|---|---|---|
Market Cap | $39.92B | $8.16B |
Volume | 1,982,609 | 1,735,121 |
Sector | Media | Health |
52-Week High | $188.46 | $59.06 |
52-Week Low | $125.61 | $26.94 |
Typical Hold Time | 72 Days | 16 Days |
Enterprise Value | $42.13B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $170.33, down 0.3% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $25.20B in 2025, with net income of $496M, though margins remain thin at 1.96%. Recent news highlights strong fan demand and strategic partnerships, such as the Salesforce Agentforce expansion announced September 16, 2026. Analyst consensus is strongly bullish with a $208.18 price target, supported by 40 buy ratings.
The outlook for LYV is positive due to robust demand for live events and double-digit growth in deferred revenue, but risks include high valuation multiples, legal uncertainties from past DOJ scrutiny, and cost pressures. Earnings volatility is a concern after recent misses, though Q2 2026 beat expectations. Investors should weigh strong institutional support against execution risks in a competitive market.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
